The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
ELISA: Use at a concentration of 0.25 - 1.0 µg/ml. Used in conjunction with compatible secondary reagents allows the detection of at least 0.2 - 0.4 ng/well of recombinant Human CXCL11.
sELISA: Use at a concentration of 0.25 - 1.0 µg/ml. Used in conjunction with a suitable capture antibody allows the detection of at least 0.2 - 0.4 ng/well of recombinant Human CXCL11.
WB: Use at a concentration of 0.1 - 0.2 µg/ml. Used in conjunction with compatible secondary reagents the detection limit for recombinant Human CXCL11 is 1.5 - 3.0 ng/lane, under either reducing or non-reducing conditions. Predicted molecular weight: 10 kDa.
Not yet tested in other applications.
Optimal dilutions/concentrations should be determined by the end user.
Chemotactic for interleukin-activated T-cells but not unstimulated T-cells, neutrophils or monocytes. Induces calcium release in activated T-cells. Binds to CXCR3. May play an important role in CNS diseases which involve T-cell recruitment. May play a role in skin immune responses.
High levels in peripheral blood leukocytes, pancreas and liver astrocytes. Moderate levels in thymus, spleen and lung. Low levels in placenta, prostate and small intestine. Also found in epidermal basal layer keratinocytes in skin disorders.
Belongs to the intercrine alpha (chemokine CxC) family.